Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. - Wikidata - wikimedia - TriplyDB

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

http://www.wikidata.org/entity/Q41756273

about

Novel agents in the treatment of multiple myeloma: a review about the future First line vs delayed transplantation in myeloma: Certainties and controversies Treatment of relapsed and refractory multiple myeloma Multiple myeloma in the very elderly patient: challenges and solutions Monoclonal antibodies targeting CD38 in hematological malignancies and beyond Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis European perspective on multiple myeloma treatment strategies in 2014 Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies The Danish National Multiple Myeloma Registry The role of maintenance therapy in multiple myeloma Recent advances in multiple myeloma: a Korean perspective Cost-effectiveness of bortezomib for multiple myeloma: a systematic review Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date Combination therapeutics in complex diseases Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice The role of SLAMF7 in multiple myeloma: impact on therapy.Are maintenance and continuous therapies indicated for every patient with multiple myeloma?Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.The Value of Patient Reported Outcomes and Other Patient-Generated Health Data in Clinical Hematology.Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.Expanding role of lenalidomide in hematologic malignancies Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program.Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years.Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma.Fasting regulates EGR1 and protects from glucose- and dexamethasone-dependent sensitization to chemotherapy.Myeloma today: Disease definitions and treatment advances.Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution.Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma Lenalidomide (Revlimid): A Thalidomide Analogue in Combination With Dexamethasone For the Treatment of All Patients With Multiple Myeloma.Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology

P2860

Q26745924-F768DC26-AEDA-455D-83FE-A6FC471984EA Q26745957-A3F15D58-E21C-45EF-8AFC-61221E8BD346 Q26749180-9D482A59-A436-4238-8DAF-955548111D38 Q26752991-7E763A71-CCA8-40B3-8925-7A662DFD9861 Q26766718-AF301708-9491-484D-942C-C86633313DA8 Q26767418-BFE9EF41-720A-4E25-94F4-A58B2AACC77D Q27005966-0C49899D-0EFA-4EC4-A245-F654667C1F61 Q27026478-45745ADF-095B-4BA6-9A23-96F7AE35D2D0 Q28067187-8B182A44-656D-4B3C-A088-69F5A9A433AA Q28071644-8C3D5825-9BBA-4F34-A551-955BD6F53EFA Q28074521-44B9C889-0FF8-4991-90D2-39EA33FF9303 Q28075297-B48EFAF9-4A1E-46F9-B34D-083F6E67A89A Q28076147-2BB382B0-5E43-4A8B-8919-5659B30BF194 Q28076891-110A6D5B-93F1-4657-B367-B1102A30B5D5 Q28077567-8F728EB5-6674-435B-A130-B891144742A1 Q30249167-818ADF72-E70A-4E2C-BE38-915AB9E14CCF Q30249790-ECA8B21C-E02D-46EE-A9FB-D09F1488A3AC Q30276010-FB3E55DF-373D-4C6A-AAAA-7BAC7065A4B3 Q30964688-60E4A9B0-1BDD-41B3-B962-3302AF75A6C9 Q31136560-304523A0-9C4A-4F8B-BAB6-A871FDCBF3A5 Q33418712-3E16FAC2-EE15-4103-98C8-171484307B70 Q33433453-ED8183FC-7D93-4F92-9EAB-75805E82ACC6 Q33441702-07135A22-F6DD-46FC-AE3E-85F480C72386 Q33443406-644DA105-44EA-4D78-B4B3-E29B0DB69603 Q33914056-9107FED9-D4B6-4CCB-91C3-509422D5C799 Q34551324-605701AF-F4A0-43EA-8D32-3FC0A1A7B030 Q35220639-9D2BE83E-4940-4CE0-BB99-AA2211C0FA5C Q35592305-241C446E-7ED6-4ABD-A622-43185698EBB4 Q35669893-0086F38E-426F-4ACA-A1E6-769CF142C3B0 Q35907586-B1DF1B39-316C-4DB2-81E4-98A849F1DDD7 Q36051084-2E47B608-31DF-467C-9F1B-51DC5F8841A4 Q36115686-C91F487B-FD1B-4EB4-A4B6-EC5E84428886 Q36254255-41FBBB96-6562-4D22-ADB2-5A3EF43EA653 Q36328064-7AFB9B99-DEC1-4B93-9F29-F05BBE7DAC45 Q36470699-2E22D1DD-A5C4-44E8-B215-93E90048D45B Q36611288-3862CD40-AF47-4091-8665-B75C1E278B88 Q36706899-FB587841-409C-4516-86D2-3DE5FA84060A Q36750472-C4844C88-CB33-4B91-872E-0DFD39561A19 Q36848023-CC37B1AF-A7E4-4EE1-9FFF-3690454B0D85 Q36963203-B811681F-35E8-4AB1-815A-B18DC5CB03CB

P2860

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

http://www.wikidata.org/entity/Q41756273

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

@en

type

label

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

@en

prefLabel

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

@en

P1433

Q41756273-5C7936AB-C50F-4A5C-990A-AA24BF99E40B

P1476

Q41756273-57E575BD-E30A-47B1-A60E-2F64590509D7

P2093

Q41756273-178E6E22-02F6-42C5-8795-175E4EFE20BF

Q41756273-21EC1484-E734-48FE-ABF5-1CB8CEC8F5D6

Q41756273-22EB5D10-6E99-4BC4-A210-6992917695C1

Q41756273-28E73B70-9B88-4BD8-8889-6530D57EFCF3

Q41756273-344EA3BB-175C-487C-A3E5-DD8C4E3D9B16

Q41756273-3CC8ADE2-DF31-4BB6-A118-0B3C1894A8B3

Q41756273-3D1D7C84-5F80-4271-8181-A8304ABDA5A1

Q41756273-4D77D3F6-75E8-4E45-93DA-B7A55E091841

Q41756273-585CB825-2667-4188-83C4-D45A072510CA

Q41756273-6FD1B99C-0C96-496D-9529-E3470667ABB4

P304

Q41756273-AF4C843A-C064-4071-93EF-DB101406753F

P31

Q41756273-0B1F2D14-5006-445F-9D83-EBB76A3BB0D3

P356

Q41756273-485A3D11-15A1-4498-9D8F-7660EDEC0371

P407

Q41756273-6CE52BD2-E421-4293-9A50-54290622F842

P433

Q41756273-6FC465AE-BF1E-4B25-B26F-6282E17FEA2B

P478

Q41756273-03EBE7B1-E489-439C-9264-1EE4812796D7

P50

Q41756273-211C0DDB-8007-4D8A-A0E9-6F9749E030F2

Q41756273-2B4CE15C-7476-4998-9C00-2EE825CE4223

Q41756273-327A7C69-7153-437A-820C-B293D561A352

Q41756273-397130BD-10F3-4509-8561-47370C71D954

Q41756273-3B8E8032-C265-4866-8D17-A309D73F68C3

Q41756273-58610500-E0DF-46DD-A00B-D1A1558967FB

Q41756273-5CA816AF-DC37-4403-BDCE-F3FA54B5C573

Q41756273-6971CFF0-1AC6-4D2D-BB6C-63B9FEBBDC88

Q41756273-92A2695A-2156-476F-9631-A67559F2015E

Q41756273-B4913BBB-7BA0-4A54-A7A3-AED04BD5B380

P577

Q41756273-68AEE2A8-BFEE-4445-AB0D-A2ADDB7F4E0D

P698

Q41756273-2293F1EA-EE84-4833-8CA2-7D995C2EF7ED

P921

Q41756273-BD38E0C6-98EA-4751-A5EA-2CAA23B3E7DB

P356

P1433

The New England Journal of Medicine

P1476

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

@en

P2093

Andrew R Belch

http://www.w3.org/2001/XMLSchema#string

Anne Banos

http://www.w3.org/2001/XMLSchema#string

Annette Ervin-Haynes

http://www.w3.org/2001/XMLSchema#string

Antonello Pinto

http://www.w3.org/2001/XMLSchema#string

Christian Jacques

http://www.w3.org/2001/XMLSchema#string

Christine Chen

http://www.w3.org/2001/XMLSchema#string

Cyrille Hulin

http://www.w3.org/2001/XMLSchema#string

Daniel Binder

http://www.w3.org/2001/XMLSchema#string

Darrell J White

http://www.w3.org/2001/XMLSchema#string

FIRST Trial Team

http://www.w3.org/2001/XMLSchema#string

P304

906-917

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1402551

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

371

http://www.w3.org/2001/XMLSchema#string

P50

Angela Dispenzieri

Meletios A. Dimopoulos

Javier de la Rubia

Catarina Geraldes

Herve Avet-Loiseau

Kenneth C Anderson

Philippe Moreau

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25184863

http://www.w3.org/2001/XMLSchema#string

P921